Adapting PlcC-NetB Fusion Proteins for Human Health Applications

This inventive concept leverages the core technology of the original patent to develop novel vaccines and treatments for various human health issues, including dental caries, acne, respiratory infections, Clostridium difficile infection, and fungal infections.

The original patent focused on preventing necrotic enteritis in poultry using PlcC-NetB fusion proteins. However, the limitations of the original patent lie in its restricted application to the poultry industry. This inventive concept addresses the need for adaptable vaccine technologies to combat human diseases, which are often caused by distinct pathogens and require targeted interventions.

The new claims expand the original patent's technology to develop PlcC-NetB fusion proteins tailored for human health applications. Specifically, the inventive concept involves modifying the NetB protein unit to target specific human pathogens, such as Streptococcus mutans for dental caries, Propionibacterium acnes for acne, and Candida albicans for fungal infections. The PlcC protein unit remains operably linked to the modified NetB protein unit via a peptide linker, enabling the fusion protein to elicit an immune response against the targeted pathogens. The inventive concept encompasses various administration methods, including vaccines, topical creams, and inhalers, to provide effective treatments for a range of human diseases.

The new claims introduce a significant departure from the original patent by adapting the PlcC-NetB fusion protein technology for human health applications. The inventive step lies in the modification of the NetB protein unit to target specific human pathogens, which enables the development of novel vaccines and treatments for various diseases.

Alternative embodiments of the inventive concept could involve the use of different peptide linkers, varying the sequence identity of the PlcC and NetB protein units, or incorporating additional protein components to enhance the immune response. Variations of the administration methods, such as oral or injectable formulations, could also be explored to expand the range of potential treatments.

The inventive concept has significant commercial potential in the human health industry, with potential applications in vaccine development, dermatology, and infectious disease treatment. The target market includes pharmaceutical companies, biotechnology firms, and research institutions focused on developing novel treatments for human diseases.